Theravance Biopharma Inc(TBPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 7:30 PM ET (Korea 9/15 08:30)
Full metrics table
| Index | RUT | P/E | 16.87 | EPS (ttm) | 1.01 | Insider Own | 6.17% | Shs Outstand | 51.9M | Perf Week | -0.29% |
| Market Cap | 0.88B | Forward P/E | 9.13 | EPS next Y | -35.47% | Insider Trans | -10.63% | Shs Float | 48.7M | Perf Month | 0.65% |
| Enterprise Value | 0.57B | PEG | - | EPS next Q | 0.28 | Inst Own | 93.09% | Short Float | 3.32% | Perf Quarter | 2.34% |
| Income | 0.05B | P/S | 8.48 | EPS this Y | 40.27% | Inst Trans | -0.93% | Short Ratio | 2.52 | Perf Half Y | 23.58% |
| Sales | 0.10B | P/B | 3.05 | EPS next 5Y | -9.64% | ROA | 12.01% | Short Interest | 1.62M | Perf YTD | -8.98% |
| Book/sh | 5.58 | P/C | 2.28 | EPS past 3/5Y | - | ROE | 20.91% | 52W High | -19.02% ($21.03) | Perf Year | 19.09% |
| Cash/sh | 7.47 | P/FCF | 16.46 | Sales past 3/5Y | 27.91% 8.38% | ROIC | 15.36% | 52W Low | 30.2% ($13.08) | Perf 3Y | 75.39% |
| Dividend Est. | - | EV/EBITDA | 70.98 | EPS Y/Y TTM | 331.61% | Gross Margin | 94.45% | Volatility(W/M) | 0.26% 0.34% | Perf 5Y | 111.82% |
| Dividend TTM | - | EV/Sales | 5.44 | Sales Y/Y TTM | 35.11% | Oper. Margin | 2.12% | ATR (14) | 0.07 | Perf 10Y | -46.26% |
| Dividend Ex-Date | - | Quick Ratio | 13.54 | EPS Q/Q | -110.56% | Profit Margin | 51.58% | RSI (14) | 55.04 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.54 | Sales Q/Q | -20.86% | SMA20 | 0.04% ($17.02) | Beta | 0.19 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.25 | Earnings | 2026/8/10 | SMA50 | 0.45% ($16.95) | Rel Volume | 0.38 | Prev Close | $17.01 |
| Employees | 90 | LT Debt/Eq | 0.21 | EPS/Sales Surpr. | -251.72% -7.84% | SMA200 | -1.32% ($17.26) | Avg Volume(3M) | 0.64M | Price | $17.03 |
| IPO | 2014/5/16 | Option/Short | Yes/Yes | Trades | 2361 | Volume | 243,262 | Change | 0.12% |
Company
TBPH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Theravance Biopharma is a biotech company built around respiratory therapeutic assets. It shares the U.S. commercialization revenue from its lead asset, YUPELRI (revefenacin) inhalation solution, with its partner, while also collecting revenue from royalties on partner assets such as the legacy TRELEGY royalty. The ticker is TBPH. Recently, the company has significantly scaled back its in-house drug development and restructured its business around a royalty and revenue collection model.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
TBPH makes money exceptionally well
2.12% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +40.3% this year.
Tap to view numbers
The price looks about right
Trading at 16.9 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by +75.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 93.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.02%
BBP 0.01%
PILL 0.01%
XPH 0.01%
FDLS 0.01%It ranks #4 in the industry
Based on market cap of $884M.
TBPH $884M PER 16.9
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is TBPH?
TBPH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TBPH?
The market cap of TBPH is approximately $884M, ranking 2,733 within its sector.
What is the P/E ratio of TBPH?
TBPH has a P/E ratio of approximately 16.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TBPH?
TBPH has recorded a 52-week high of $21.03 and a low of $13.08.
